UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1236 - 1244
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Confidence Intervals | Prognosis | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Male | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Squamous Cell - mortality | Neoplasm Invasiveness - pathology | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Development and progression | Care and treatment | Cross infection | Nosocomial infections | Erlotinib | Lung cancer, Non-small cell | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 663 - 671
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Brain Neoplasms - diagnostic imaging | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Small Cell Lung Carcinoma - drug therapy | Small Cell Lung Carcinoma - secondary | Early Termination of Clinical Trials | Brain Neoplasms - secondary | Aged, 80 and over | Medical Futility | Adult | Female | Survival Rate | Cranial Irradiation - adverse effects | Brain Neoplasms - prevention & control | Small Cell Lung Carcinoma - prevention & control | Magnetic Resonance Imaging | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Small Cell Lung Carcinoma - diagnostic imaging | Watchful Waiting | Aged | Platinum Compounds - administration & dosage | Care and treatment | Chemotherapy | Lung cancer | Oncology, Experimental | Radiation | Clinical trials | Metastasis | Research | College teachers | Radiotherapy | Cancer | Analysis | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 12, pp. 1643 - 1652
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | ErbB Receptors - antagonists & inhibitors | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Piperazines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Tyrosine | Lung cancer, Non-small cell | Analysis | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 874 - 886
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Sulfones - therapeutic use | Pyrazoles - therapeutic use | gamma-Glutamyltransferase - blood | Humans | Middle Aged | Sulfones - adverse effects | Lung Neoplasms - pathology | Male | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Carcinoma, Non-Small-Cell Lung - secondary | Anaplastic Lymphoma Kinase | Adult | Female | Pyridines - therapeutic use | Crizotinib | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Docetaxel | Disease Progression | Disease-Free Survival | Retreatment | Aspartate Aminotransferases - blood | Receptor Protein-Tyrosine Kinases - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - therapeutic use | Pyrimidines - therapeutic use | Gene Rearrangement | Pyrimidines - adverse effects | Carcinoma, Non-Small-Cell Lung - drug therapy | Platinum Compounds - administration & dosage | Neoplasm Staging | Care and treatment | Chemotherapy | Lymphomas | Research institutes | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1147 - 1157
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Humans | Middle Aged | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Etoposide - administration & dosage | Lung Neoplasms - pathology | Male | Survival Rate | Small Cell Lung Carcinoma - drug therapy | Cisplatin - administration & dosage | Neoplasm Recurrence, Local - pathology | Small Cell Lung Carcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Adult | Camptothecin - administration & dosage | Female | Aged | Neoplasm Staging | Camptothecin - analogs & derivatives | Medical colleges | Care and treatment | Relapse | Chemotherapy | Lung cancer | Etoposide | Respiratory agents | Product development | College teachers | Diseases | Cancer | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Metastasis | Kinases | Evidence-based medicine | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
The lancet respiratory medicine, ISSN 2213-2600, 2016, Volume 5, Issue 1, pp. 42 - 50
Pulmonary/Respiratory | Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Piperidines - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Middle Aged | Male | Treatment Outcome | Antineoplastic Agents - administration & dosage | Disease-Free Survival | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Gene Order | Proto-Oncogene Proteins c-ret - genetics | Treatment outcome | Care and treatment | Vandetanib | Safety and security measures | Analysis | Dosage and administration | Lung cancer, Non-small cell | Clinical trials | Usage | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 1, pp. 106 - 113
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - mortality | Humans | Middle Aged | Etoposide - administration & dosage | Lung Neoplasms - pathology | Male | Lung Neoplasms - therapy | Carcinoma, Small Cell - mortality | Chemoradiotherapy | Cisplatin - administration & dosage | Carcinoma, Small Cell - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Camptothecin - administration & dosage | Dose Fractionation | Female | Aged | Carcinoma, Small Cell - pathology | Neoplasm Staging | Camptothecin - analogs & derivatives | Medical colleges | Care and treatment | Nuclear radiation | Lung cancer | Etoposide | College teachers | Radiotherapy | Index Medicus
Journal Article
Lung cancer (Amsterdam, Netherlands), ISSN 0169-5002, 2016, Volume 99, pp. 186 - 193
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Non-small-cell lung cancer | Randomized phase II trial | Ramucirumab | Japan | Docetaxel | Respiratory System | Oncology | Life Sciences & Biomedicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Platinum - administration & dosage | Taxoids - therapeutic use | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Risk Factors | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Taxoids - pharmacokinetics | Retreatment | Taxoids - administration & d